Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.47 |
| ▸ | HRH2 | P25021 | 5/20 | 0.44 |
| ▸ | HRH1 | P35367 | 5/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21667892 | 0.87 | HRH3 (0.49) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL9917378 | 0.87 | HRH3 (0.49) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL9917377 | 0.87 | HRH3 (0.49) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL13542804 | 0.83 | HRH3 (0.46) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL13543540 | 0.83 | HRH3 (0.46) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL24114470 | 0.78 | HRH3 (0.49) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL12717290 | 0.78 | HRH3 (0.49) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL9921265 | 0.78 | HRH3 (0.49) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL20729439 | 0.78 | HRH3 (0.49) | HRH3HRH2HRH1HTR1APDCD1 | |
| SCHEMBL13552419 | 0.78 | HRH3 (0.49) | HRH3HRH2HRH1HTR1APDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759458-B2 | Indane-amines as PD-L1 antagonists | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759458-B2 | Indane-amines as PD-L1 antagonists | CD274, PDCD1LG2, PDCD1 | HRH3 11/4885HRH2 21/4885HRH1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.